{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '7.8.', 'Treatment after the End of the Study', 'Participants will not receive any additional treatment from GSK after completion of the', 'study because other treatment options are available.', 'The Investigator is responsible for ensuring that consideration has been given to the post-', \"study care of the participant's medical condition.\", 'At the end of the treatment period (Visit 5), or after study treatment Discontinuation', 'Visit, or withdrawal from study, participants can resume conventional COPD therapy as', 'prescribed by the Investigator. Post-treatment concomitant medication should be entered', 'into the eCRF until the safety follow-up visit for participants that successfully complete', 'Visit 5 on study treatment and for participants that withdraw from the study. For', 'participants that discontinue study treatment, post-treatment concomitant medication', 'should be entered into the eCRF until they complete the visit/telephone contact at the', 'planned Visit 6 date.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', 'Participants that permanently stop study treatment should return to the clinic as soon as', 'possible, in order to complete the Study Treatment Discontinuation Visit. The evaluations', 'and procedures to be completed are outlined in the SoA (Section 2).', 'Participants that discontinue study treatment are encouraged to remain in the study and', 'every effort should be made by the Investigator/staff to keep the participant in the study,', 'to collect important efficacy and safety data by telephone contact. Ideally, participants', 'should return to the clinic to complete Visit 5, to collect important spirometry data,', \"however, if this isn't possible, this visit should also be completed by telephone. A safety\", 'follow-up phone call (Visit 6) should also be conducted 7 days after Visit 5.', 'The Investigator/site staff should contact the participant by telephone at the protocol', 'designated visit time intervals to collect the following:', 'SAEs', 'AEs assessed as related to study participation', 'AEs resulting in withdrawal from the study', 'COPD exacerbations', 'Concomitant medication', 'Spirometry (Visit 5 only, if participant consents)', 'Participants have the right to discontinue study treatment before the end of the study. A', \"participant may also be asked to discontinue study treatment at the Investigator's\", 'discretion.', '57']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'A participant may be withdrawn from study treatment at any time. A reason for', 'premature discontinuation of study treatment (e.g., AE, lack of efficacy, protocol', 'deviation, Investigator discretion, consent withdrawn etc.) must be captured in the', 'eCRF Protocol defined criteria for discontinuation of study treatment', 'A participant must be permanently discontinued from study treatment if any of the', 'following stopping criteria are met:', 'Liver chemistry stopping and increased monitoring criteria have been designed', 'to assure participant safety and evaluate liver event etiology (in alignment with the', 'FDA premarketing clinical liver safety guidance). These protocol guidelines are in', 'alignment with FDA premarketing clinical liver safety guidance:', 'http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/', 'Guidances/UCM174090.pd', 'Discontinuation of study treatment for abnormal liver tests should be considered by', 'the Investigator when a participant meets one of the conditions outlined in the', 'algorithm or if the Investigator believes that it is in the best interest of the', 'participant.', 'Liver Safety Algorithms and Required Actions and Follow up Assessments can be', 'found in Appendix 4.', 'Pregnancy: Positive urine pregnancy test.', 'QTc Stopping Criteria:', 'Details on performing ECG assessments can be found in Section 9.4.3', 'The same QT correction formula must be used for each individual participant', 'to determine eligibility for and discontinuation from the study. This formula', 'may not be changed or substituted once the participant has been enrolled.', 'Safety ECGs and other non-protocol specified ECGs are an exception.', 'For example, if a participant is eligible for the protocol based on QT', \"interval corrected for heart rate by Bazett's formula (QTcB), then QTcB\", 'must be used for discontinuation of this individual participant as well.', \"Once the QT correction formula has been chosen for a participant's\", 'eligibility, the same formula must continue to be used for that participant', 'for all QTc data being collected for data analysis.', 'The QTc should be based on averaged QTc values of triplicate', 'electrocardiograms obtained over a brief (e.g., 5-10 minute) recording period.', 'For this study, the following QTc stopping criteria will apply and lead to', 'withdrawal from study treatment:', 'an increase in QTc by > 60 msec from baseline or', 'development of a QTc > 530 msec (based on an average of triplicate', 'ECGs)', '58']\n\n###\n\n", "completion": "END"}